160 related articles for article (PubMed ID: 36468997)
1. [Radioactive iodine in the treatment of Graves' disease: history and modern concept of radionuclide therapy].
Sheremeta MS; Korchagina MO; Pesheva ED; Fadeev VV
Ter Arkh; 2022 Nov; 94(10):1211-1215. PubMed ID: 36468997
[TBL] [Abstract][Full Text] [Related]
2. Follicular carcinoma of the thyroid following radioactive iodine treatment for Graves' disease.
Staffurth JS; Holl-Allen RT
Postgrad Med J; 1988 Nov; 64(757):878-80. PubMed ID: 3255938
[TBL] [Abstract][Full Text] [Related]
3. [Radioiodine treatment of benign thyroid diseases].
Konrády A
Orv Hetil; 2006 Sep; 147(37):1783-9. PubMed ID: 17131798
[TBL] [Abstract][Full Text] [Related]
4. Radioactive Iodine: A Living History.
Daniels GH; Ross DS
Thyroid; 2023 Jun; 33(6):666-673. PubMed ID: 37307104
[No Abstract] [Full Text] [Related]
5. The effect of propylthiouracil on subsequent radioactive iodine therapy in Graves' disease.
Hancock LD; Tuttle RM; LeMar H; Bauman J; Patience T
Clin Endocrinol (Oxf); 1997 Oct; 47(4):425-30. PubMed ID: 9404440
[TBL] [Abstract][Full Text] [Related]
6. Quantitative measurement of thyroid blood flow for differentiation of painless thyroiditis from Graves' disease.
Ota H; Amino N; Morita S; Kobayashi K; Kubota S; Fukata S; Kamiyama N; Miyauchi A
Clin Endocrinol (Oxf); 2007 Jul; 67(1):41-5. PubMed ID: 17437515
[TBL] [Abstract][Full Text] [Related]
7. Radioactive iodine ablation therapy: a viable option in the management of Graves' disease in Nigeria.
Adedapo KS; Fadiji IO; Orunmuyi AT; Onimode Y; Osifo BO
Afr J Med Med Sci; 2012 Dec; 41 Suppl():193-6. PubMed ID: 23678656
[TBL] [Abstract][Full Text] [Related]
8. Papillary thyroid carcinoma in cervical lymph nodes with vanished thyroid gland after ablation of Graves' disease by radioactive iodine.
Hamdy O; Raafat S; Saleh GA; Atallah K; M Saleh M; Shebl AM; Hegazy MA
Ann R Coll Surg Engl; 2019 May; 101(5):e122-e124. PubMed ID: 30854863
[TBL] [Abstract][Full Text] [Related]
9. The effect of antithyroid drug pretreatment on acute changes in thyroid hormone levels after (131)I ablation for Graves' disease.
Burch HB; Solomon BL; Cooper DS; Ferguson P; Walpert N; Howard R
J Clin Endocrinol Metab; 2001 Jul; 86(7):3016-21. PubMed ID: 11443161
[TBL] [Abstract][Full Text] [Related]
10. Effect of previous administration of potassium iodine and different durations of low iodine diets for radioiodine therapy on the treatment of Graves' disease in iodine-rich areas.
Tamura M; Nakada K; Iwanaga H; Fujita N; Kato K
Eur J Nucl Med Mol Imaging; 2024 Mar; 51(4):1060-1069. PubMed ID: 38008728
[TBL] [Abstract][Full Text] [Related]
11. Histologic Findings and Cytological Alterations in Thyroid Nodules After Radioactive Iodine Treatment for Graves' Disease: A Diagnostic Dilemma.
El Hussein S; Omarzai Y
Int J Surg Pathol; 2017 Jun; 25(4):314-318. PubMed ID: 28201927
[TBL] [Abstract][Full Text] [Related]
12. Radioiodine treatment in pediatric Graves' disease and thyroid carcinoma.
Yuan L; Yang J
J Pediatr Endocrinol Metab; 2011; 24(11-12):877-83. PubMed ID: 22308835
[TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy of fixed-dose radioactive iodine for the treatment of hyperthyroidism at a single centre: our experience.
Nair D; Maweni R; Constantinou C; Kandiah S; Nagala S; Aung T
Ir J Med Sci; 2022 Aug; 191(4):1659-1665. PubMed ID: 34537910
[TBL] [Abstract][Full Text] [Related]
14. International differences in approaches to 131I therapy for Graves' disease: case selection and restrictions recommended to patients in Japan, Korea, and China.
Tominaga T; Yokoyama N; Nagataki S; Cho BY; Koh CS; Chen JL; Shi Y
Thyroid; 1997 Apr; 7(2):217-20. PubMed ID: 9133688
[TBL] [Abstract][Full Text] [Related]
15. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists.
Bahn Chair RS; Burch HB; Cooper DS; Garber JR; Greenlee MC; Klein I; Laurberg P; McDougall IR; Montori VM; Rivkees SA; Ross DS; Sosa JA; Stan MN; ;
Thyroid; 2011 Jun; 21(6):593-646. PubMed ID: 21510801
[TBL] [Abstract][Full Text] [Related]
16. Graves' disease induced by Na(131)I therapy for toxic multinodular goitre.
van Leussen JJ; Edelbroek MA; Talsma MA; de Heide LJ
Neth J Med; 2000 Nov; 57(5):194-7. PubMed ID: 11185482
[TBL] [Abstract][Full Text] [Related]
17. Celebrating eighty years of radionuclide therapy and the work of Saul Hertz.
Fahey FH; Grant FD
J Appl Clin Med Phys; 2021 Jan; 22(1):4-10. PubMed ID: 33533204
[TBL] [Abstract][Full Text] [Related]
18. The Accomplishments and Legacy of Saul Hertz, MD.
Greenspan BS; Hofman MS; Buscombe J
J Nucl Med; 2024 Apr; 65(4):659-663. PubMed ID: 38453358
[TBL] [Abstract][Full Text] [Related]
19. Predictive factors for the outcomes of Graves' disease patients with radioactive iodine (131I) treatment.
Xing YZ; Zhang K; Jin G
Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31840740
[TBL] [Abstract][Full Text] [Related]
20. [Definitive treatment of Graves' disease in children].
Ivannikova TE; Shiryaeva TY; Nagaeva EV; Sheremeta MS; Brovin DN; Bezlepkina OB
Probl Endokrinol (Mosk); 2022 Apr; 68(2):104-111. PubMed ID: 35488761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
